Cargando…

Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma

Purpose: Gold standard beam radiation for glioblastoma (GBM) treatment is challenged by resistance phenomena occurring in cellular populations well prepared to survive or to repair damage caused by radiation. Among signals that have been linked with radio-resistance, the SDF1/CXCR4 axis, associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Séhédic, Delphine, Chourpa, Igor, Tétaud, Clément, Griveau, Audrey, Loussouarn, Claire, Avril, Sylvie, Legendre, Claire, Lepareur, Nicolas, Wion, Didier, Hindré, François, Davodeau, François, Garcion, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695146/
https://www.ncbi.nlm.nih.gov/pubmed/29158842
http://dx.doi.org/10.7150/thno.19403
_version_ 1783280259366387712
author Séhédic, Delphine
Chourpa, Igor
Tétaud, Clément
Griveau, Audrey
Loussouarn, Claire
Avril, Sylvie
Legendre, Claire
Lepareur, Nicolas
Wion, Didier
Hindré, François
Davodeau, François
Garcion, Emmanuel
author_facet Séhédic, Delphine
Chourpa, Igor
Tétaud, Clément
Griveau, Audrey
Loussouarn, Claire
Avril, Sylvie
Legendre, Claire
Lepareur, Nicolas
Wion, Didier
Hindré, François
Davodeau, François
Garcion, Emmanuel
author_sort Séhédic, Delphine
collection PubMed
description Purpose: Gold standard beam radiation for glioblastoma (GBM) treatment is challenged by resistance phenomena occurring in cellular populations well prepared to survive or to repair damage caused by radiation. Among signals that have been linked with radio-resistance, the SDF1/CXCR4 axis, associated with cancer stem-like cell, may be an opportune target. To avoid the problem of systemic toxicity and blood-brain barrier crossing, the relevance and efficacy of an original system of local brain internal radiation therapy combining a radiopharmaceutical with an immuno-nanoparticle was investigated. Experiment design: The nanocarrier combined lipophilic thiobenzoate complexes of rhenium-188 loaded in the core of a lipid nanocapsule (LNC(188)Re) with a function-blocking antibody, 12G5 directed at the CXCR4, on its surface. The efficiency of 12G5-LNC(188)Re was investigated in an orthotopic and xenogenic GBM model of CXCR4-positive U87MG cells implanted in the striatum of Scid mice. Results: We demonstrated that 12G5-LNC(188)Re single infusion treatment by convection-enhanced delivery resulted in a major clinical improvement in median survival that was accompanied by locoregional effects on tumor development including hypovascularization and stimulation of the recruitment of bone marrow derived CD11b- or CD68-positive cells as confirmed by immunohistochemistry analysis. Interestingly, thorough analysis by spectral imaging in a chimeric U87MG GBM model containing CXCR4-positive/red fluorescent protein (RFP)-positive- and CXCR4-negative/RFP-negative-GBM cells revealed greater confinement of DiD-labeled 12G5-LNCs than control IgG2a-LNCs in RFP compartments. Main conclusion: These findings on locoregional impact and targeting of disseminated cancer cells in tumor margins suggest that intracerebral active targeting of nanocarriers loaded with radiopharmaceuticals may have considerable benefits in clinical applications.
format Online
Article
Text
id pubmed-5695146
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-56951462017-11-20 Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma Séhédic, Delphine Chourpa, Igor Tétaud, Clément Griveau, Audrey Loussouarn, Claire Avril, Sylvie Legendre, Claire Lepareur, Nicolas Wion, Didier Hindré, François Davodeau, François Garcion, Emmanuel Theranostics Research Paper Purpose: Gold standard beam radiation for glioblastoma (GBM) treatment is challenged by resistance phenomena occurring in cellular populations well prepared to survive or to repair damage caused by radiation. Among signals that have been linked with radio-resistance, the SDF1/CXCR4 axis, associated with cancer stem-like cell, may be an opportune target. To avoid the problem of systemic toxicity and blood-brain barrier crossing, the relevance and efficacy of an original system of local brain internal radiation therapy combining a radiopharmaceutical with an immuno-nanoparticle was investigated. Experiment design: The nanocarrier combined lipophilic thiobenzoate complexes of rhenium-188 loaded in the core of a lipid nanocapsule (LNC(188)Re) with a function-blocking antibody, 12G5 directed at the CXCR4, on its surface. The efficiency of 12G5-LNC(188)Re was investigated in an orthotopic and xenogenic GBM model of CXCR4-positive U87MG cells implanted in the striatum of Scid mice. Results: We demonstrated that 12G5-LNC(188)Re single infusion treatment by convection-enhanced delivery resulted in a major clinical improvement in median survival that was accompanied by locoregional effects on tumor development including hypovascularization and stimulation of the recruitment of bone marrow derived CD11b- or CD68-positive cells as confirmed by immunohistochemistry analysis. Interestingly, thorough analysis by spectral imaging in a chimeric U87MG GBM model containing CXCR4-positive/red fluorescent protein (RFP)-positive- and CXCR4-negative/RFP-negative-GBM cells revealed greater confinement of DiD-labeled 12G5-LNCs than control IgG2a-LNCs in RFP compartments. Main conclusion: These findings on locoregional impact and targeting of disseminated cancer cells in tumor margins suggest that intracerebral active targeting of nanocarriers loaded with radiopharmaceuticals may have considerable benefits in clinical applications. Ivyspring International Publisher 2017-10-12 /pmc/articles/PMC5695146/ /pubmed/29158842 http://dx.doi.org/10.7150/thno.19403 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Séhédic, Delphine
Chourpa, Igor
Tétaud, Clément
Griveau, Audrey
Loussouarn, Claire
Avril, Sylvie
Legendre, Claire
Lepareur, Nicolas
Wion, Didier
Hindré, François
Davodeau, François
Garcion, Emmanuel
Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title_full Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title_fullStr Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title_full_unstemmed Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title_short Locoregional Confinement and Major Clinical Benefit of (188)Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
title_sort locoregional confinement and major clinical benefit of (188)re-loaded cxcr4-targeted nanocarriers in an orthotopic human to mouse model of glioblastoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695146/
https://www.ncbi.nlm.nih.gov/pubmed/29158842
http://dx.doi.org/10.7150/thno.19403
work_keys_str_mv AT sehedicdelphine locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT chourpaigor locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT tetaudclement locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT griveauaudrey locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT loussouarnclaire locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT avrilsylvie locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT legendreclaire locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT lepareurnicolas locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT wiondidier locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT hindrefrancois locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT davodeaufrancois locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma
AT garcionemmanuel locoregionalconfinementandmajorclinicalbenefitof188reloadedcxcr4targetednanocarriersinanorthotopichumantomousemodelofglioblastoma